Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.53 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.53 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.53 |
| ▸ | HINT1 | P49773 | 5/20 | 0.53 |
| ▸ | F2 | P00734 | 3/20 | 0.52 |
| ▸ | POLA1 | P09884 | 1/20 | 0.50 |
| ▸ | GSK3A | P49840 | 2/20 | 0.46 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.46 |
| ▸ | TYMP | P19971 | 1/20 | 0.45 |
| ▸ | PNP | P00491 | 1/20 | 0.45 |
| ▸ | KRAS | P01116 | 1/20 | 0.44 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.43 |
| ▸ | NT5E | P21589 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5352650 | 1.00 | POLB (0.60) | POLBP2RY2P2RY4P2RY6HINT1 | |
| SCHEMBL5352210 | 1.00 | POLB (0.60) | POLBP2RY2P2RY4P2RY6HINT1 | |
| SCHEMBL5357283 | 1.00 | POLB (0.60) | POLBP2RY2P2RY4P2RY6HINT1 | |
| SCHEMBL5347882 | 0.93 | POLB (0.63) | POLBP2RY2P2RY4P2RY6HINT1 | |
| SCHEMBL5355041 | 0.91 | HINT1 (0.50) | POLBP2RY2P2RY4P2RY6HINT1 | |
| SCHEMBL8447610 | 0.91 | HINT1 (0.50) | POLBP2RY2P2RY4P2RY6HINT1 | |
| SCHEMBL5352518 | 0.91 | HINT1 (0.50) | POLBP2RY2P2RY4P2RY6HINT1 | |
| SCHEMBL22875468 | 0.91 | HINT1 (0.50) | POLBP2RY2P2RY4P2RY6HINT1 | |
| SCHEMBL5357715 | 0.87 | POLB (0.62) | POLBP2RY2P2RY4P2RY6HINT1 | |
| SCHEMBL5347297 | 0.87 | POLA1 (0.55) | POLBP2RY2P2RY4P2RY6HINT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7307166-B1 | Oxpurine nucleosides and their congeners, and acyl, derivatives thereof, for improvement of hematopoiesis | WELLSTAT THERAPEUTICS CORPORATION (US) | 2007-12-11 | — | — | US | disclosed |
| US-20040235782-A1 | Oxypurine nucleosides and their congeners, and acyl derivatives thereof, for improvement of hematopoiesis | PRO-NEURON, INC. | 2004-11-25 | — | — | US | disclosed |
| EP-1157698-A2 | Treatment of inflammatory diseases with oxypurine nucleosides | PRO-NEURON, INC. (US) | 2001-11-28 | — | — | EP | disclosed |
| US-6060459-A | Enhancing blood cell count with oxypurine nucleosides | PRO-NEURON, INC. (US) | 2000-05-09 | — | — | US | disclosed |
| US-6054441-A | Antiinflammatory agents; treatment of bacterial, viral or fungal infections; autoimmune diseases | PRO-NEURON, INC. (US) | 2000-04-25 | — | — | US | disclosed |
| EP-0570519-B1 | OXYPURINE NUCLEOSIDES AND THEIR CONGENERS, AND ACYL DERIVATIVES THEREOF, FOR IMPROVEMENT OF HEMATOPOIESIS | PRO NEURON INC (US) | 1999-05-06 | — | — | EP | disclosed |
| EP-0771204-A1 | METHODS FOR TREATING SEPSIS OR INFLAMMATORY DISEASES WITH OXYPURINE NUCLEOSIDES | PRO-NEURON, INC. (US) | 1997-05-07 | — | — | EP | disclosed |
| EP-0570519-A4 | OXYPURINE NUCLEOSIDES AND THEIR CONGENERS, AND ACYL DERIVATIVES THEREOF, FOR IMPROVEMENT OF HEMATOPOIESIS | PRO NEURON INC (US) | 1996-02-21 | — | — | EP | disclosed |
| EP-0570519-A1 | OXYPURINE NUCLEOSIDES AND THEIR CONGENERS, AND ACYL DERIVATIVES THEREOF, FOR IMPROVEMENT OF HEMATOPOIESIS | PRO-NEURON, INC. (US) | 1993-11-24 | — | — | EP | disclosed |
| WO-1992013561-A1 | OXYPURINE NUCLEOSIDES AND THEIR CONGENERS, AND ACYL DERIVATIVES THEREOF, FOR IMPROVEMENT OF HEMATOPOIESIS | PRO-NEURON, INC. (US) | 1992-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235782-A1 | Oxypurine nucleosides and their congeners, and acyl derivatives thereof, for improvement of hematopoiesis | TPMT, NUDT1, ENTPD5 | POLB 799/4885P2RY2 399/4885P2RY4 226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.